PMID- 31727510
OWN - NLM
STAT- MEDLINE
DCOM- 20210129
LR  - 20211204
IS  - 1938-0682 (Electronic)
IS  - 1558-7673 (Linking)
VI  - 18
IP  - 1
DP  - 2020 Feb
TI  - Real-world Clinical Outcomes of Pazopanib Immediately After Discontinuation of 
      Immunotherapy for Advanced Renal Cell Carcinoma.
PG  - e37-e45
LID - S1558-7673(19)30314-3 [pii]
LID - 10.1016/j.clgc.2019.10.010 [doi]
AB  - INTRODUCTION: In the first-line (1L) setting, pazopanib (PAZ) has been 
      recommended by the National Comprehensive Cancer Network for the treatment of 
      advanced renal cell carcinoma (aRCC). In 2018, immuno-oncology (IO) therapy 
      became a commonly used 1L treatment option for aRCC. We report the real-world 
      clinical outcomes of PAZ after IO therapy for patients with aRCC. MATERIALS AND 
      METHODS: We performed a longitudinal, retrospective medical record review study. 
      The included patients were aged >/= 18 years, had initiated second-line and/or 
      beyond PAZ after IO therapy for clear cell aRCC on or before October 2017, and 
      had complete medical records available from the diagnosis of aRCC to the 
      discontinuation of PAZ, death, or the medical record extraction date (May 2018), 
      whichever occurred first. The primary outcome variable was the PAZ duration of 
      therapy. The secondary outcomes were progression-free survival and overall 
      survival since PAZ initiation, the reasons for PAZ discontinuation, and the 
      occurrence of adverse events (AEs). RESULTS: A total of 258 eligible patients had 
      initiated IO therapies before PAZ as follows: nivolumab (68%), nivolumab plus 
      ipilimumab (14%), pembrolizumab (12%), and ipilimumab (3%). Overall, the median 
      PAZ duration of therapy was 13.4 months (95% confidence interval [CI], 10.1-16.0 
      months). The median progression-free survival with PAZ after IO therapy was 13.5 
      months (95% CI, 11.8 months to not reached). The estimated overall survival rate 
      of PAZ after IO therapy at 6 and 12 months was 93% and 89%, respectively. A total 
      of 109 patients (42%) had reported an AE. The most frequently reported AEs were 
      fatigue (29%) and diarrhea (14%). No additional safety signal of hepatotoxicity 
      was observed (increased aspartate aminotransferase, 5%; increased alanine 
      transaminase, 6%). CONCLUSIONS: In the present real-world study, second-line 
      and/or beyond PAZ after previous IO therapy was well-tolerated and effective for 
      patients with aRCC.
CI  - Copyright (c) 2019 Elsevier Inc. All rights reserved.
FAU - Cao, Xiting
AU  - Cao X
AD  - Novartis Pharmaceuticals Corporation, East Hanover, NJ. Electronic address: 
      xiting.cao@novartis.com.
FAU - Tang, Derek
AU  - Tang D
AD  - Novartis Pharmaceuticals Corporation, East Hanover, NJ.
FAU - Ratto, Barbara
AU  - Ratto B
AD  - Novartis Pharmaceuticals Corporation, East Hanover, NJ.
FAU - Poole, Austin
AU  - Poole A
AD  - Huntsman Cancer Institute, Salt Lake City, UT.
FAU - Ravichandran, Shoba
AU  - Ravichandran S
AD  - Novartis Pharmaceuticals Corporation, East Hanover, NJ.
FAU - Jin, Lixian
AU  - Jin L
AD  - Novartis Pharmaceuticals Corporation, East Hanover, NJ.
FAU - Gao, Wei
AU  - Gao W
AD  - Analysis Group, Inc., Boston, MA.
FAU - Swallow, Elyse
AU  - Swallow E
AD  - Analysis Group, Inc., Boston, MA.
FAU - Vogelzang, Nicholas J
AU  - Vogelzang NJ
AD  - Comprehensive Cancer Centers of Nevada, Henderson, NV.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20191016
PL  - United States
TA  - Clin Genitourin Cancer
JT  - Clinical genitourinary cancer
JID - 101260955
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antineoplastic Agents, Immunological)
RN  - 0 (Indazoles)
RN  - 0 (Ipilimumab)
RN  - 0 (Pyrimidines)
RN  - 0 (Sulfonamides)
RN  - 31YO63LBSN (Nivolumab)
RN  - 7RN5DR86CK (pazopanib)
RN  - DPT0O3T46P (pembrolizumab)
SB  - IM
MH  - Aged
MH  - Antibodies, Monoclonal, Humanized/administration & dosage
MH  - Antineoplastic Agents, Immunological/*administration & dosage
MH  - Antineoplastic Combined Chemotherapy Protocols/*administration & dosage/adverse 
      effects
MH  - Carcinoma, Renal Cell/*drug therapy/mortality/pathology
MH  - Diarrhea/chemically induced/epidemiology
MH  - Fatigue/chemically induced/epidemiology
MH  - Female
MH  - Humans
MH  - Indazoles
MH  - Ipilimumab/administration & dosage
MH  - Kidney Neoplasms/*drug therapy/mortality/pathology
MH  - Male
MH  - Middle Aged
MH  - Nivolumab/administration & dosage
MH  - Progression-Free Survival
MH  - Pyrimidines/*administration & dosage/adverse effects
MH  - Retrospective Studies
MH  - Sulfonamides/*administration & dosage/adverse effects
MH  - Time Factors
OTO - NOTNLM
OT  - Immuno-oncology
OT  - Real-world outcomes
OT  - Targeted therapy
OT  - Treatment patterns
OT  - aRCC
EDAT- 2019/11/16 06:00
MHDA- 2021/01/30 06:00
CRDT- 2019/11/16 06:00
PHST- 2019/07/30 00:00 [received]
PHST- 2019/10/07 00:00 [accepted]
PHST- 2019/11/16 06:00 [pubmed]
PHST- 2021/01/30 06:00 [medline]
PHST- 2019/11/16 06:00 [entrez]
AID - S1558-7673(19)30314-3 [pii]
AID - 10.1016/j.clgc.2019.10.010 [doi]
PST - ppublish
SO  - Clin Genitourin Cancer. 2020 Feb;18(1):e37-e45. doi: 10.1016/j.clgc.2019.10.010. 
      Epub 2019 Oct 16.